Detalhe da pesquisa
1.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407001
2.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36542826
3.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547003
4.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
5.
Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report.
J Natl Compr Canc Netw
; 21(2): 102-107, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791756
6.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
J Natl Compr Canc Netw
; 21(11): 1118-1131, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935098
7.
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Cancer
; 128(8): 1595-1604, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157306
8.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
J Natl Compr Canc Netw
; 20(6): 622-634, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714675
9.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
J Natl Compr Canc Netw
; 19(11): 1218-1230, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34781267
10.
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(6): 755-781, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502987
11.
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.
Am J Hematol
; 95(6): 583-593, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32170769
12.
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
J Natl Compr Canc Netw
; 17(6): 650-661, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200358
13.
Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Blood
; 127(9): 1128-37, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26675347
14.
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Blood
; 138(9): 811-814, 2021 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34189565
15.
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.
J Natl Compr Canc Netw
; 16(3): 245-254, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29523663
16.
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Cancer
; 123(22): 4411-4418, 2017 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28749548
17.
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(5): 608-638, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28476741
18.
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
J Natl Compr Canc Netw
; 15(3): 293-311, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275031
19.
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
Am J Hematol
; 92(2): 161-170, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27880984
20.
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Br J Haematol
; 175(4): 631-640, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27469075